Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature

Table 1

Case reports/series of checkpoint inhibitor-induced GBS.

Cases	Checkpoint inhibitor	GBS variant	Treatment	Outcome
Wilgenhof and Neyns [14]	Ipilimumab/CTLA-4	AIDP	Corticosteroids	Recovery
Bot et al. [15]	Ipilimumab/CTLA-4	AIDP	IVIG	Death
Gaudy-Marqueste et al. [16]	Ipilimumab/CTLA-4	Enteric neuropathy	Corticosteroids, anti-TNF therapy, tacrolimus, plasmapheresis, orogastric drainage, and ventilatory assistance	Death
Jacob et al. [23]	Nivolumab/PD-1	AIDP	IVIG, plasmapheresis, and intubation	Death
Patel et al. [17]	Ipilimumab/CTLA-4	AIDP	Corticosteroids, IVIG	Recovery
Supakornnumporn and Katirji [18]	Combination ipilimumab+nivolumab	AIDP	Corticosteroids, IVIG, and nasogastric tube	Recovery
Wu et al. [5]	Ipilimumab/CTLA-4	Pandysautonomia	Corticosteroids, IVIG, pressors, intubation, indwelling urinary catheter, and TPN	Recovery
Fukumoto et al. [24]	Nivolumab/PD-1	AIDP	Corticosteroids, IVIG	Recovery
Garcia et al. [3]	Ipilimumab/CTLA-4	AIDP	Corticosteroids	Recovery
Kyriazoglou et al. [27]	Nivolumab/PD-1	AIDP	Corticosteroids, IVIG	Recovery
Manam et al.—2 cases [19]	Pembrolizumab/PD-1 ×2	(1) AIDP; (2) AIDP	(1) Corticosteroids, IVIG, and plasmapheresis; (2) Corticosteroids, IVIG, intubation, and plasmapheresis	(1) Recovery; (2) Death
Nukui et al. [25]	Nivolumab/PD-1	AIDP	Corticosteroids, IVIG	Recovery
Ong et al. [20]	Pembrolizumab/PD-1	AIDP	Corticosteroids, IVIG	Recovery
Thapa et al. [26]	Nivolumab/PD-1	AIDP	Corticosteroids, IVIG, and intubation	Prevention of disease progression

AIDP = acute inflammatory demyelinating polyneuropathy; IVIG = intravenous immunoglobulin; TNF = tissue necrosis factor; TPN = total parenteral nutrition.